China Pharma (NYSE:CPHI) (NYSE: CPHI) is a leading integrated pharmaceutical company headquartered in Beijing, specializing in the research, development, manufacturing and distribution of active pharmaceutical ingredients (APIs), generic drugs and innovative specialty medications. Founded in 2005, the company has grown from a regional API supplier into one of China’s foremost exporters of finished dosage forms, serving both domestic hospitals and global pharmaceutical partners. China Pharma’s product portfolio spans therapeutic areas such as cardiovascular, oncology, anti‐infectives and central nervous system treatments, reflecting its commitment to addressing critical health needs.
The company’s operations are built around a network of state‐of‐the‐art manufacturing facilities across China, including campuses in Jiangsu and Anhui provinces. These facilities adhere to stringent quality and regulatory standards, including Good Manufacturing Practice (GMP) certifications from both Chinese authorities and key overseas regulators. China Pharma leverages advanced process engineering and continuous manufacturing technologies to optimize production efficiency, reduce costs and ensure consistent product quality.
Research and development is a core pillar of China Pharma’s strategy. The company maintains dedicated R&D centers in Beijing and Shanghai, where multidisciplinary teams of chemists, biologists and formulation scientists focus on both small‐molecule drug discovery and the development of complex generics. In recent years, China Pharma has expanded its pipeline through strategic alliances with academic institutions and biotech firms, targeting novel targets in oncology and metabolic disease. These collaborations have also accelerated the company’s export strategy, facilitating regulatory filings in North America, Europe and select Asia‐Pacific markets.
Under the leadership of Chief Executive Officer John Wang, China Pharma has pursued a balanced growth model centered on sustainable investment in innovation, operational excellence and global market expansion. The management team emphasizes strong governance and transparent reporting, with an eye on long‐term value creation for stakeholders. As healthcare systems worldwide continue to demand cost‐effective and high‐quality pharmaceutical solutions, China Pharma is positioned to play a significant role in meeting that demand through both its established commercial offerings and evolving research pipeline.
